The effect of combination pharmacotherapy on the prescription trends of glaucoma medications

Journal of Glaucoma

Volumn 14, Issue 2, 2005, Pages 157-160

  Kaiserman, Igor ^a   Kaiserman, Nadia ^a   Nakar, Sasson ^b,c   Vinker, Shlomo ^b,c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c CLALIT HEALTH SERVICES   (Israel)

Author keywords

Adrenergic antagonists; Dorzolamide; Fixed combination pharmacotherapy; Glaucoma medications; Prescription trends

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LEVOBUNOLOL; PILOCARPINE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; TIMOLOL;

ARTICLE; CLINICAL EDUCATION; CLINICAL PROTOCOL; DRUG CHOICE; DRUG FORMULATION; DRUG UTILIZATION; GLAUCOMA; HEALTH MAINTENANCE ORGANIZATION; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MANAGED CARE; MEDICAL RECORD; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACIST; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL;

ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; DRUG UTILIZATION; GLAUCOMA, OPEN-ANGLE; HEALTH MAINTENANCE ORGANIZATIONS; HEALTH SERVICES RESEARCH; HEALTH SURVEYS; HUMANS; INTRAOCULAR PRESSURE; ISRAEL; OCULAR HYPERTENSION; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 15244363172     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ijg.0000151889.59165.3d     Document Type: Article

References (20)

1. Marchetti A, Magar R, An P, et al. Clinical and economic impact of new trends in glaucoma treatment. MedGenMed. 2001;3:6.
2. Martinez GS, Campbell AJ, Reinken J, et al. Prevalence of ocular disease in a population study of subjects 65 years old and older. Am J Ophthalmol. 1982;94:181-189.
3. Gibson JM, Rosenthal AR, Lavery J. A study of the prevalence of eye disease in the elderly in an English community. Trans Ophthalmol Soc U K. 1985;104:196-203.
4. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991;266:369-374.
5. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 1992;99:1499-1504.
6. Coffey M, Reidy A, Wormald R, et al. Prevalence of glaucoma in the west of Ireland. Br J Ophthalmol. 1993;77:17-21.
7. Dielemans I, Vingerling JR, Wolfs RC, et al. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology. 1994;101:1851-1855.
8. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38:83-91.
9. Tuck MW, Crick RP. The age distribution of primary open angle glaucoma. Ophthalmic Epidemiol. 1998;5:173-183.
10. Bateman DN, Clark R, Azuara Blanco A, et al. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care. Br J Ophthalmol. 2002;86:551-554.
11. Cohen E, Goldschmid A, Garty M. Fixed-dose combination therapy in the United States, Britain and Israel. Isr Med Assoc J. 2001;3:572-574.
12. Truter I, Kotze TJ. An investigation into the prescribing of analgesics. S Afr Med J. 1996;86:1394-1397.
13. Rushton JL, Whitmire JT. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998. Arch Pediatr Adolesc Med. 2001;155:560-565.
14. Malhotra S, Karan RS, Pandhi P, et al. Pattern of use and pharmacoeconomic impact of antihypertensive drugs in a north Indian referral hospital. Eur J Clin Pharmacol. 2001;57:535-540.
15. Jassim Al Khaja KA, Sequeira RP, Mathur VS. Patterns of utilization of antihypertensive drug combinations in Bahrain: do they conform with international guidelines? Int J Clin Pharmacol Ther. 2000;38: 568-580.
16. Wells BJ, Lobel KD, Dickerson LM. Using the electronic medical record to enhance the use of combination drugs. Am J Med Qual. 2003;18: 147-149.
17. Stewart WC, Leech J, Sharpe ED, et al. An economic analysis of switching to latanoprost from a. Am J Manag Care. 2002;8:S240-S248.
18. Zabriskie N, Netland PA. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials. Adv Ther. 2003;20:92-100.
19. Dasgupta S, Oates V, Bookhart BK, et al. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care. 2002;8:S255-S261.
20. Bohn RL, Gurwitz JH, Yeomans SM, et al. Which patients are treated for glaucoma? An observational analysis. J Glaucoma. 2000;9:38-44.